A brief introductory video explaining Micropore's unique membrane-based system
Our unique technology
Back to Latest News
Micropore Technologies today announced a Collaboration & Licence Agreement with InnoCore Technologies BV, Groningen, The Netherlands to deploy its patented technology, for the manufacture of InnoCore’s SynBiosys® long acting injectable drugs.
InnoCore has developed sophisticated biodegradable polymer formulation technologies for long acting injectable, sustained release microparticle-based drug delivery products. Its SynBiosys® biodegradable polymer platform enables systemic and site-specific parenteral drug delivery of small molecule, peptide and protein drugs with extended release duration from days up to several months.
Micropore’s patented, GMP standard, high-throughput membrane encapsulation technology will allow InnoCore to continuously produce precisely controlled high-quality encapsulated products at volumes previously only possible using traditional homogenisation techniques, but with significantly more predictability and significantly higher yields and reduced processing costs.
Through enabling InnoCore to process more evenly sized micro-particles, Micropore’s equipment will result in products offering more precisely controllable dose levels with narrower release time parameters because unwanted rupture variability in the product can be virtually eliminated.
In addition, because Micropore’s unique patented technology is based on a crossflow technique utilising tubular membranes, with no moving parts, the minimal shear forces involved in producing the microcapsules will help to protect the sensitive biological drugs that InnoCore’s microparticle products incorporate from processing damage – significantly reducing wastage (which can be up to 50% using traditional encapsulation techniques) also reducing processing energy by around a 30% - all of which will contribute to a positive impact on the end cost of InnoCore’s products.
We are delighted with this symbiotic collaboration. We have been looking for the opportunity to demonstrate the inherent advantages of our technology in a cGMP application. Our capability of delivering near-monodispersity in formulations and encapsulated particles will enable InnoCore to optimise the efficacy of their long acting injectable controlled-release formulations and facilitate scale-up for high volume throughput production
Dai Hayward, CEO Micropore
At Micropore we enjoy working in partnership with our clients to solve formulation challenges and deliver the highest performing, most sustainable, most cost-effective formulated delivery systems.Ask An Expert
Keep up to date with innovations at Micropore. Sign up today to stay informed with innovations at Micropore and automatically receive the Micropore newsletter and webinar invites.